Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

Goldman Sachs raised the firm’s price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company’s Q3 results and announced deal with Novartis (NVS) involving ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical ...

Schrödinger (NASDAQ:SDGR) shares traded higher on Tuesday despite reporting lower-than-expected Q3 2024 financials after the ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The ...